ProMIS Neurosciences, Inc. (PMN) Stock Score, Valuation & Financial Research

ProMIS Neurosciences, Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for PMN

ProMIS Neurosciences, Inc. does not currently have a complete Wall Street Score. The stored market price is USD 9.21. These figures are a research snapshot, not a buy or sell recommendation.

What ProMIS Neurosciences, Inc. does

ProMIS Neurosciences, Inc. is a Canadian biotechnology firm dedicated to creating targeted therapeutic solutions for debilitating neurodegenerative conditions such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA). The company leverages a unique computational discovery platform, utilizing its ProMIS and Collective Coordinates algorithms, to identify novel, disease-specific targets – known as epitopes – located on the surface of misfolded proteins. Its pipeline features several promising drug candidates, including PMN310, a monoclonal antibody designed to address toxic oligomers implicated in Alzheimer's disease. Another candidate, PMN267, targets superoxide dismutase 1 and TAR-DNA binding protein 43 in ALS, and alpha-synuclein associated with Parkinson's disease and Lewy body dementia. Finally, PMN442 is a monoclonal antibody aimed at toxic alpha-synuclein oligomers and seeding fibrils relevant to multiple system atrophy. Established in 2004, the company changed its name from Amorfix Life Sciences Ltd. to ProMIS Neurosciences, Inc. in July 2015. Its corporate headquarters are situated in Toronto, Canada.

Company business and revenue

Research reporting period: 2025-12-31. A research update is not a new financial filing.

How the company makes money

ProMIS Neurosciences is a clinical-stage biotechnology company that generates no commercial revenue. It operates by funding the research and development of proprietary antibody therapies and vaccines for neurodegenerative diseases, relying on capital raises and equity financing to sustain its operations until potential future commercialization or licensing of its drug candidates.

Products and services

  • The company develops a pipeline of antibody therapies and vaccines targeting toxic misfolded proteins, including its lead candidate PMN310 for Alzheimer's disease, as well as candidates for ALS, multiple system atrophy, and other neurodegenerative conditions.

Suppliers, materials and equipment

  • Contract Research Organizations (CROs) — The company relies on third-party CROs to manage and conduct its clinical trials and patient registration. Source

Business strengths to evaluate

  • Proprietary computational discovery platform (EpiSelect) Source

Business risks and research considerations

  • History of operating losses and dependence on additional financing Source
  • Uncertainty of clinical trial success and regulatory approval Source

Sources: Company research source

Company research refreshed 2026-10-12. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

PMN financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 9.21
Market capitalization:
82.59M (currency not supplied)
Revenue:
USD 0.00
Net income:
USD -42.23M
Free cash flow:
USD -28.12M
Cash:
USD 53.43M
Total debt:
USD 0.00
EPS:
USD -16.89

What stands out

  • Free cash flow is USD -28.12M, negative for the stored period.
  • The balance sheet shows USD 53.43M of cash versus USD 0.00 of total debt, an excess of cash over debt on these two reported measures.
  • The current research record carries a fundamental change risk warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Cash exceeds debt by USD 53.43M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for PMN

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • How long can PMN fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • How is PMN likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
  • What specifically needs to improve for PMN to reach sustainable profitability?
  • What does the current fundamental change risk warning mean for the reliability or interpretation of PMN's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-01.

Research-input completeness: 55% of the scoring inputs required for this public page are currently available.

How to research PMN

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.